Industry9 min read
Generic Semaglutide: Live Abroad, US Locked Till 2031
Semaglutide generics launched in India and Canada in 2026 at $14-78 a month. US patents run to December 2031. What US buyers can source now.
Peptide News & Analysis
FDA actions, trial readouts, vendor coverage and pricing reports — curated for peptide buyers and clinicians.
Daily Peptide News
New articles delivered to your inbox every morning. Free.
Latest News
Industry12 min read
GLP-1 Bone Loss: What the 5-Year Data Actually Shows
Five-year records on 73,483 GLP-1 users show higher osteoporosis rates — but only in some groups. The numbers, the mechanism, what people track.
Industry7 min read
HM17321: Roche's $2.3B Muscle-Sparing Obesity Peptide
Roche paid $190M upfront for HM17321, a urocortin-2 analog that raised lean mass while cutting fat in monkeys. What it changes for GLP-1 users now.
Industry9 min read
Can You Mix Peptides in the Same Syringe?
Which peptide pairs get combined in one syringe, which never are, and why pre-blended vials sidestep the question. Sorted by pH, stability and sterility.
Industry6 min read
Yale Study: Semaglutide Needs Hunger Neurons for Fat Loss
A PNAS study found semaglutide switches ON AgRP hunger neurons — and disrupting them blunts fat loss. Why returning appetite isn't the same as failure.
Industry7 min read
Retatrutide Early Access: Who Actually Qualifies
Lilly opened retatrutide early access before FDA approval. Four criteria gate it, three parties sign off — and why almost nobody gets through.
Industry7 min read
Hims Peptide Launch: What Ships, What Waits on FDA
Hims & Hers will sell sermorelin, glutathione and NAD+ by year-end. BPC-157 and five more wait on FDA rulemaking — the timeline, and where they sell now.
Industry11 min read
GLP-1s and Birth Control: What the Labels Require
Tirzepatide cut oral contraceptive exposure 20%; semaglutide showed none. New Aug 2026 consensus guidelines. Which compounds carry the warning.
Trials10 min read
GLP-1s and PMOS (PCOS): What the Trial Data Shows
A semaglutide analysis in PMOS — the condition formerly called PCOS — reported 52% lower testosterone and more regular cycles. What the data shows.
Industry10 min read
Is Retatrutide a Biologic? The FDA Fight Explained
A court sent FDA back to the drawing board on retatrutide's classification. The 41st amino acid decides whether it can ever be compounded.
Trials9 min read
Ribupatide: 19.2% Weight Loss and No Way to Buy It
Kailera's ribupatide (KAI-9531) hit 19.2% weight loss in China's Phase 3 and is now in global trials. Why it isn't for sale — and what ships today.
Industry16 min read
Lilly Sues 6 Retatrutide Sellers: Who's Affected
Eli Lilly filed six suits on August 12 over retatrutide sales. The named defendants, the payment-processor ask, and what actually changes for buyers.
Trials8 min read
Once-Yearly Semaglutide Implant: Phase 1 Dosing Done
Vivani dosed all 20 subjects in SLIM-1, the first human trial of a once-yearly semaglutide implant. Novo is evaluating it. What buyers can use now.
Industry9 min read
GLP-1 Antitrust Suit Tossed: What Changes for Buyers
A Texas judge dismissed Strive's antitrust case against Lilly and Novo, ruling compounded GLP-1s never competed with the branded drugs at all.
Industry5 min read
GLP-3 RT Peptide: What It Is, Codes & Prices
GLP-3 RT is a vendor code name for retatrutide. So are ION-3R, EZP-3P and R-30. Every coded SKU decoded, plus what each one costs per mg.
Industry5 min read
How to Verify a Peptide COA: 6 Checks
A vendor founder went to prison for forging lab certificates. Six checks that separate a real Certificate of Analysis from a PDF that proves nothing.
Industry8 min read
Compounded GLP-1 State Laws: Who Restricts What
California codified a stricter copy rule, Ohio suspended 30+ licenses, Washington issued stop-service orders. The state layer now gates compounded GLP-1s.
Vendors5 min read
Is Ascend Science Legit? Reviews, COAs & Prices
A 15-month-old vendor with unusually strong lab documentation and almost no reputation yet. What their COAs really show, and how the pricing compares.